PYXS Stock Summary and Trading Ideas (Pyxis Oncology | NASDAQ:PYXS)

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Pyxis Oncology trades on the NASDAQ stock market under the symbol PYXS.

As of March 14, 2025, PYXS stock price climbed to $1.11 with 494,270 million shares trading.

PYXS has a beta of 0.39, meaning it tends to be less sensitive to market movements. PYXS has a correlation of 0.00 to the broad based SPY ETF.

PYXS has a market cap of $65.96 million. This is considered a Micro Cap stock.

In the last 3 years, PYXS traded as high as $6.92 and as low as $.99.

The top ETF exchange traded funds that PYXS belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

PYXS has underperformed the market in the last year with a return of -79.3%, while the SPY ETF gained +10.4%. In the last 3 month period, PYXS fell short of the market, returning -31.5%, while SPY returned -6.5%. However, in the most recent 2 weeks PYXS has outperformed the stock market by returning -1.8%, while SPY returned -3.8%.

PYXS support price is $1.02 and resistance is $1.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PYXS shares will trade within this expected range on the day.